These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25602110)

  • 1. Vemurafenib and cobimetinib in BRAF-mutated melanoma.
    Rahman A
    Lancet Oncol; 2014 Nov; 15(12):e535. PubMed ID: 25602110
    [No Abstract]   [Full Text] [Related]  

  • 2. Cobimetinib.
    Signorelli J; Shah Gandhi A
    Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.
    de la Cruz-Merino L; Di Guardo L; Grob JJ; Venosa A; Larkin J; McArthur GA; Ribas A; Ascierto PA; Evans JTR; Gomez-Escobar A; Barteselli G; Eng S; Hsu JJ; Uyei A; Dréno B
    J Transl Med; 2017 Jun; 15(1):146. PubMed ID: 28646893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
    Kawaguchi K; Murakami T; Chmielowski B; Igarashi K; Kiyuna T; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
    Oncotarget; 2016 Nov; 7(44):71737-71743. PubMed ID: 27690220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.
    Kawaguchi K; Igarashi K; Murakami T; Zhao M; Zhang Y; Chmielowski B; Kiyuna T; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM
    J Cell Biochem; 2017 Aug; 118(8):2314-2319. PubMed ID: 28106277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.
    Abdel-Wahab O; Klimek VM; Gaskell AA; Viale A; Cheng D; Kim E; Rampal R; Bluth M; Harding JJ; Callahan MK; Merghoub T; Berger MF; Solit DB; Rosen N; Levine RL; Chapman PB
    Cancer Discov; 2014 May; 4(5):538-45. PubMed ID: 24589925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
    Keating GM
    Drugs; 2016 Apr; 76(5):605-15. PubMed ID: 26984388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular approaches to tumor inhibition in melanoma.
    Davies MA
    Clin Adv Hematol Oncol; 2015 Dec; 13(12):831-3. PubMed ID: 27058849
    [No Abstract]   [Full Text] [Related]  

  • 9. Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.
    Mey UJM; Renner C; von Moos R
    Hematol Oncol; 2017 Dec; 35(4):890-893. PubMed ID: 27641727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
    Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
    N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Expression Profiling in
    Wongchenko MJ; McArthur GA; Dréno B; Larkin J; Ascierto PA; Sosman J; Andries L; Kockx M; Hurst SD; Caro I; Rooney I; Hegde PS; Molinero L; Yue H; Chang I; Amler L; Yan Y; Ribas A
    Clin Cancer Res; 2017 Sep; 23(17):5238-5245. PubMed ID: 28536307
    [No Abstract]   [Full Text] [Related]  

  • 12. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
    Dréno B; Ribas A; Larkin J; Ascierto PA; Hauschild A; Thomas L; Grob JJ; Koralek DO; Rooney I; Hsu JJ; McKenna EF; McArthur GA
    Ann Oncol; 2017 May; 28(5):1137-1144. PubMed ID: 28444112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
    Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
    Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cobimetinib/vemurafenib-associated bilateral serous retinopathy: a case report].
    Kastl G
    Ophthalmologe; 2019 Aug; 116(8):785-788. PubMed ID: 30357465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.
    Eagles JR; Jimeno A
    Drugs Today (Barc); 2016 Nov; 52(11):593-605. PubMed ID: 28112278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
    Amaral T; Nouri N; Garbe C
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib.
    Flaherty KT; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Oct; 10(11):811-2. PubMed ID: 22037033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?
    Saint-Jean M; Quéreux G; Nguyen JM; Peuvrel L; Brocard A; Vallée A; Knol AC; Khammari A; Denis MG; Dréno B
    J Invest Dermatol; 2014 May; 134(5):1468-1470. PubMed ID: 24025553
    [No Abstract]   [Full Text] [Related]  

  • 20. Cobimetinib and vemurafenib for the treatment of melanoma.
    Boespflug A; Thomas L
    Expert Opin Pharmacother; 2016; 17(7):1005-11. PubMed ID: 26999478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.